Quest Diagnostics (DGX) Tops Q3 EPS by 58c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $255.68 +3.49%
Financial Fact:
Income tax expense: -95M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Income tax expense: -95M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $4.31, $0.58 better than the analyst estimate of $3.73. Revenue for the quarter came in at $2.79 billion versus the consensus estimate of $2.73 billion.
GUIDANCE:
Quest Diagnostics sees FY2020 EPS of $9.00-$10.00, versus the consensus of $8.71. Quest Diagnostics sees FY2020 revenue of $8.8-9.1 billion, versus the consensus of $8.74 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Steris (STE) Tops Q3 EPS by 26c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
